Dishman Carbogen Amcis Ltd. AI Stock Analysis
Want to see IN:DCAL full AI Analyst Report?
Dishman Carbogen Amcis Ltd. (DCAL) AI Stock Analysis
Dishman Carbogen Amcis Ltd.
(NSE:DCAL)
IN:DCAL receives a moderate score largely weighed down by highly bearish technical momentum, as the stock is trading well below key moving averages. While underlying financial performance is stabilizing with renewed profitability and steady top-line growth, margin pressures and a moderately high P/E ratio cap the near-term upside.
Dishman Carbogen Amcis Ltd. (DCAL) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 18.36B
- Dividend Yield
- ―
- Average Volume (3M)
- 21.00K
- Price to Earnings (P/E)
- 27.2
- Beta (1Y)
- 1.38
- Revenue Growth
- -0.11%
- EPS Growth
- -184.93%
- Country
- India
- Employees
- 934
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Dishman Carbogen Amcis Ltd. Business Overview & Revenue Model
Company Description
Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited provides specialized contract research and manufacturing solutions to the worldwide pharmaceutical sector. The company operates through two main business segmen...
Dishman Carbogen Amcis Ltd. Financial Statement Overview
Summary
Reflects a mixed but improving profile with steady revenue growth and a recent return to net profitability, supported by a solid equity base. However, this is tempered by a recent contraction in gross profit, historical free cash flow volatility, and a rising debt load.
Income Statement
68PositiveBalance Sheet
72PositiveCash Flow
65Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.92B | 29.32B | 27.11B | 26.16B | 23.15B | 21.41B |
| Gross Profit | 5.69B | 7.37B | 22.10B | 18.45B | 17.81B | 16.82B |
| EBITDA | 4.44B | 5.62B | 4.73B | 3.07B | 3.08B | 3.43B |
| Net Income | 682.52M | 974.50M | 32.40M | -1.53B | -298.00M | 180.10M |
Balance Sheet | ||||||
| Total Assets | 0 | 119.23B | 99.99B | 95.81B | 94.53B | 86.37B |
| Cash, Cash Equivalents and Short-Term Investments | 10.07B | 10.07B | 5.32B | 4.31B | 3.09B | 4.67B |
| Total Debt | 0 | 30.76B | 23.89B | 23.13B | 22.09B | 18.30B |
| Total Liabilities | -66.77B | 52.46B | 41.68B | 39.54B | 36.44B | 30.89B |
| Stockholders Equity | 66.77B | 66.77B | 58.32B | 56.27B | 58.10B | 55.49B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 780.50M | 1.58B | 807.20M | -3.54B | -1.09B |
| Operating Cash Flow | 0 | 3.45B | 3.75B | 3.84B | 2.66B | 3.55B |
| Investing Cash Flow | 0 | -2.55B | -1.92B | -2.30B | -4.94B | -6.19B |
| Financing Cash Flow | 0 | 3.57B | -1.02B | -221.50M | 2.50B | 1.30B |
Dishman Carbogen Amcis Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:DCAL, the sentiment is Negative. The current price of 118.60 is below the 20-day moving average (MA) of 148.89, below the 50-day MA of 155.27, and below the 200-day MA of 175.13, indicating a bearish trend. The MACD of -5.29 indicates Positive momentum. The RSI at 29.06 is Positive, neither overbought nor oversold. The STOCH value of 2.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:DCAL.
Dishman Carbogen Amcis Ltd. Peers Comparison
Overall Rating
IN:BLUEJET71Outperform
IN:CONCORDBIO65Neutral
IN:SYNGENE60.6Neutral
IN:DCAL59Neutral
IN:ONESOURCE48Neutral
IN:BIOCON47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | INR 97.82B | 32.30 | ― | 0.23% | -7.05% | -21.25% | |
| 65Neutral | INR 116.38B | 41.26 | ― | 1.36% | 4.02% | -12.81% | |
| 61Neutral | INR 176.65B | 94.46 | ― | 0.29% | -5.99% | -60.30% | |
| 59Neutral | INR 18.59B | 27.25 | ― | ― | -0.11% | -184.93% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | INR 183.87B | -10686.00 | ― | ― | 10.66% | -104.59% | |
| 47Neutral | INR 589.95B | 121.62 | ― | 0.14% | 5.70% | -24.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:DCAL | Dishman Carbogen Amcis Ltd. | 118.60 | -118.45 | -49.97% | |
| IN:BIOCON | Biocon Limited | 362.35 | -33.58 | -8.48% | |
| IN:BLUEJET | Blue Jet Healthcare Limited | 516.80 | -37.29 | -6.73% | |
| IN:CONCORDBIO | Concord Biotech Ltd. | 556.20 | -153.55 | -21.63% | |
| IN:SYNGENE | Syngene International Ltd. | 437.60 | -190.12 | -30.29% | |
| IN:ONESOURCE | OneSource Specialty Pharma Limited | 1603.40 | -27.85 | -1.71% |
Dishman Carbogen Amcis Ltd. Corporate Events
Dishman Carbogen Amcis Adopts FY26 Standalone Accounts at Virtual AGM
Dishman Carbogen Amcis Ltd. held its 19th Annual General Meeting on September 30, 2026, via video conferencing and other audio-visual means, in compliance with Ministry of Corporate Affairs and SEBI guidelines for virtual shareholder meetings. Partic...
Dishman Carbogen Amcis Announces Cessation of Vice President (Operation)
Dishman Carbogen Amcis Limited has announced a change in senior management, disclosing that Vice President (Operation) Mr. Deepak Ram Chandra Mittal has ceased to hold his position with effect from the close of business hours on August 27, 2026.The c...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
